<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36146673</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Novel Synergistic Anti-Enteroviral Drug Combinations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1866</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14091866</ELocationID><Abstract><AbstractText><i>Background:</i> Enterovirus infections affect people around the world, causing a range of illnesses, from mild fevers to severe, potentially fatal conditions. There are no approved treatments for enterovirus infections. <i>Methods:</i> We have tested our library of broad-spectrum antiviral agents (BSAs) against echovirus 1 (EV1) in human adenocarcinoma alveolar basal epithelial A549 cells. We also tested combinations of the most active compounds against EV1 in A549 and human immortalized retinal pigment epithelium RPE cells. <i>Results:</i> We confirmed anti-enteroviral activities of pleconaril, rupintrivir, cycloheximide, vemurafenib, remdesivir, emetine, and anisomycin and identified novel synergistic rupintrivir-vemurafenib, vemurafenib-pleconaril and rupintrivir-pleconaril combinations against EV1 infection. <i>Conclusions:</i> Because rupintrivir, vemurafenib, and pleconaril require lower concentrations to inhibit enterovirus replication in vitro when combined, their cocktails may have fewer side effects in vivo and, therefore, should be further explored in preclinical and clinical trials against EV1 and other enterovirus infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ianevski</LastName><ForeName>Aleksandr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zusinaite</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Technology, University of Tartu, 50411 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenson</LastName><ForeName>Tanel</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0260-3601</Identifier><AffiliationInfo><Affiliation>Institute of Technology, University of Tartu, 50411 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oksenych</LastName><ForeName>Valentyn</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5088-3791</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afset</LastName><ForeName>Jan Egil</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Microbiology, St. Olavs Hospital, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bj&#xf8;r&#xe5;s</LastName><ForeName>Magnar</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8759-1170</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kainov</LastName><ForeName>Denis E</ForeName><Initials>DE</Initials><Identifier Source="ORCID">0000-0001-7716-6955</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Technology, University of Tartu, 50411 Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>207SMY3FQT</RegistryNumber><NameOfSubstance UI="D000077484">Vemurafenib</NameOfSubstance></Chemical><Chemical><RegistryNumber>6C74YM2NGI</RegistryNumber><NameOfSubstance UI="D000841">Anisomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>98600C0908</RegistryNumber><NameOfSubstance UI="D003513">Cycloheximide</NameOfSubstance></Chemical><Chemical><RegistryNumber>X8D5EPO80M</RegistryNumber><NameOfSubstance UI="D004640">Emetine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000841" MajorTopicYN="N">Anisomycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003513" MajorTopicYN="N">Cycloheximide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004640" MajorTopicYN="N">Emetine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010849" MajorTopicYN="Y">Picornaviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077484" MajorTopicYN="N">Vemurafenib</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral drug combination</Keyword><Keyword MajorTopicYN="N">antiviral strategy</Keyword><Keyword MajorTopicYN="N">broad-spectrum antiviral agent</Keyword><Keyword MajorTopicYN="N">echovirus</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36146673</ArticleId><ArticleId IdType="pmc">PMC9505890</ArticleId><ArticleId IdType="doi">10.3390/v14091866</ArticleId><ArticleId IdType="pii">v14091866</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 antivirals: Past, present, and future. Acta Pharm. Sin. B. 2022;12:1542&#x2013;1566. doi: 10.1016/j.apsb.2021.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug M.J., Cloud G., Bradley J., Sanchez P.J., Romero J., Powell D., Lepow M., Mani C., Capparelli E.V., Blount S., et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr. Infect. Dis. J. 2003;22:335&#x2013;341. doi: 10.1097/01.inf.0000059765.92623.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000059765.92623.70</ArticleId><ArticleId IdType="pubmed">12690273</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug M.J., Michaels M.G., Wald E., Jacobs R.F., Romero J.R., Sanchez P.J., Wilson G., Krogstad P., Storch G.A., Lawrence R., et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates with Enterovirus Sepsis. J. Pediatr. Infect. Dis. Soc. 2016;5:53&#x2013;62. doi: 10.1093/jpids/piv015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piv015</ArticleId><ArticleId IdType="pmc">PMC4765488</ArticleId><ArticleId IdType="pubmed">26407253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Herrington D.T., Coats T.L., Kim K., Cooper E.C., Villano S.A., Liu S., Hudson S., Pevear D.C., Collett M., et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. 2003;36:1523&#x2013;1532. doi: 10.1086/375069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/375069</ArticleId><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., Patick A.K., Smith G.J., 3rd, Zalman L.S. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob. Agents Chemother. 2003;47:3907&#x2013;3916. doi: 10.1128/AAC.47.12.3907-3916.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.12.3907-3916.2003</ArticleId><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.I., Ianevski A., Lysvand H., Vitkauskiene A., Oksenych V., Bjoras M., Telling K., Lutsar I., Dumpis U., Irie Y., et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int. J. Infect. Dis. 2020;93:268&#x2013;276. doi: 10.1016/j.ijid.2020.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.02.018</ArticleId><ArticleId IdType="pmc">PMC7128205</ArticleId><ArticleId IdType="pubmed">32081774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Yao R., Simonsen R.M., Myhre V., Ravlo E., Kaynova G.D., Zusinaite E., White J.M., Polyak S.J., Oksenych V., et al. Mono- and combinational drug therapies for global viral pandemic preparedness. iScience. 2022;25:104112. doi: 10.1016/j.isci.2022.104112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104112</ArticleId><ArticleId IdType="pmc">PMC8983340</ArticleId><ArticleId IdType="pubmed">35402870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Yao R., Biza S., Zusinaite E., Mannik A., Kivi G., Planken A., Kurg K., Tombak E.M., Ustav M., Jr., et al. Identification and Tracking of Antiviral Drug Combinations. Viruses. 2020;12:1178. doi: 10.3390/v12101178.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12101178</ArticleId><ArticleId IdType="pmc">PMC7589631</ArticleId><ArticleId IdType="pubmed">33080984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Simonsen R.M., Myhre V., Tenson T., Oksenych V., Bjoras M., Kainov D.E. DrugVirus.info 2.0: An integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs) Nucleic Acids Res. 2022;50:W272&#x2013;W275. doi: 10.1093/nar/gkac348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac348</ArticleId><ArticleId IdType="pmc">PMC9252782</ArticleId><ArticleId IdType="pubmed">35610052</ArticleId></ArticleIdList></Reference><Reference><Citation>Potdar S., Ianevski A., Mpindi J.P., Bychkov D., Fiere C., Ianevski P., Yadav B., Wennerberg K., Aittokallio T., Kallioniemi O., et al. Breeze: An integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics. 2020;36:3602&#x2013;3604. doi: 10.1093/bioinformatics/btaa138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa138</ArticleId><ArticleId IdType="pmc">PMC7267830</ArticleId><ArticleId IdType="pubmed">32119072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav B., Pemovska T., Szwajda A., Kulesskiy E., Kontro M., Karjalainen R., Majumder M.M., Malani D., Murumagi A., Knowles J., et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 2014;4:5193. doi: 10.1038/srep05193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep05193</ArticleId><ArticleId IdType="pmc">PMC4046135</ArticleId><ArticleId IdType="pubmed">24898935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Giri A.K., Aittokallio T. SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739&#x2013;W743. doi: 10.1093/nar/gkac382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac382</ArticleId><ArticleId IdType="pmc">PMC9252834</ArticleId><ArticleId IdType="pubmed">35580060</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.I., Krpina K., Ianevski A., Shtaida N., Jo E., Yang J., Koit S., Tenson T., Hukkanen V., Anthonsen M.W., et al. Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. Viruses. 2019;11:964. doi: 10.3390/v11100964.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11100964</ArticleId><ArticleId IdType="pmc">PMC6832696</ArticleId><ArticleId IdType="pubmed">31635418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Zusinaite E., Kuivanen S., Strand M., Lysvand H., Teppor M., Kakkola L., Paavilainen H., Laajala M., Kallio-Kokko H., et al. Novel activities of safe-in-human broad-spectrum antiviral agents. Antivir. Res. 2018;154:174&#x2013;182. doi: 10.1016/j.antiviral.2018.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.04.016</ArticleId><ArticleId IdType="pmc">PMC7113852</ArticleId><ArticleId IdType="pubmed">29698664</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider-Poetsch T., Ju J., Eyler D.E., Dang Y., Bhat S., Merrick W.C., Green R., Shen B., Liu J.O. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat. Chem. Biol. 2010;6:209&#x2013;217. doi: 10.1038/nchembio.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.304</ArticleId><ArticleId IdType="pmc">PMC2831214</ArticleId><ArticleId IdType="pubmed">20118940</ArticleId></ArticleIdList></Reference><Reference><Citation>Denisova O.V., Kakkola L., Feng L., Stenman J., Nagaraj A., Lampe J., Yadav B., Aittokallio T., Kaukinen P., Ahola T., et al. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J. Biol. Chem. 2012;287:35324&#x2013;35332. doi: 10.1074/jbc.M112.392142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.392142</ArticleId><ArticleId IdType="pmc">PMC3471742</ArticleId><ArticleId IdType="pubmed">22910914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>